

**RESPONSE TO RESTRICTION REQUIREMENT**

**Remarks**

**Co-Pending Application**

Applicants advise the Examiner of U.S.S.N. 10/488,341 filed on November 8, 2004, which is co-pending.

**Response to Restriction Requirement**

The Examiner has restricted the claims into four groups:

Group I, claims 1-43, 51, 52, and 58-76, drawn to a method for decreasing appetite, reducing hunger or sensations of hunger, increasing satiety or sensation of satiety, decreasing food intake, decreasing calorie intake, reducing nutrient availability, increasing energy expenditure, preventing, reducing or treating weight gain, inducing or promoting weight loss, maintaining a desired body weight or a desired Body Mass Index, or reducing or preventing obesity in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject;

Group II, claim 44, drawn to a pharmaceutical composition comprising a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof in admixture or conjunction with a pharmaceutically suitable carrier;

Group III, claims 45-50, drawn to a pharmaceutical composition comprising a therapeutically effective amount of PYY or an agonist thereof in admixture with a pharmaceutically suitable carrier for subcutaneous administration; and

U.S.S.N. 10/501,411

Filed: July 12, 2004

**RESPONSE TO RESTRICTION REQUIREMENT**

Group IV, claims 53-57, drawn to a method for decreasing appetite, reducing hunger or sensations of hunger, increasing satiety or sensation of satiety, decreasing food intake, decreasing calorie intake, reducing nutrient availability, increasing energy expenditure, preventing, reducing or treating weight gain, inducing or promoting weight loss, maintaining a desired body weight or a desired Body Mass Index, or reducing or preventing obesity in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof..

Applicants elect Group I, claims 1-43, 51, 52, and 58-76, without traverse.

Allowance of claims 1-43, 51, 52, and 58-76, is respectfully solicited.

Respectfully submitted,

/Patrea L. Pabst/

Patrea L. Pabst

Reg. No. 31,284

Date: December 3, 2007

PABST PATENT GROUP LLP

400 Colony Square, Suite 1200

1201 Peachtree Street

Atlanta, Georgia 30361

(404) 879-2151

(404) 879-2160 (Facsimile)